Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.45 |
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KCNQ3 | O43525 | 7/20 | 0.35 |
| ▸ | KCNQ2 | O43526 | 7/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16626220 | 1.00 | CNR2 (0.45) | CNR2CNR1HSD11B1MEN1KMT2A | |
| SCHEMBL961306 | 0.93 | CNR2 (0.44) | CNR2CNR1HSD11B1MEN1KMT2A | |
| SCHEMBL964461 | 0.93 | CNR2 (0.44) | CNR2CNR1HSD11B1MEN1KMT2A | |
| SCHEMBL961307 | 0.93 | CNR2 (0.44) | CNR2CNR1HSD11B1MEN1KMT2A | |
| SCHEMBL965811 | 0.87 | CNR2 (0.46) | CNR2CNR1HSD11B1MEN1KMT2A | |
| SCHEMBL963175 | 0.87 | CNR2 (0.46) | CNR2CNR1HSD11B1MEN1KMT2A | |
| SCHEMBL961865 | 0.87 | CNR2 (0.46) | CNR2CNR1HSD11B1MEN1KMT2A | |
| SCHEMBL964164 | 0.87 | CNR2 (0.46) | CNR2CNR1HSD11B1MEN1KMT2A | |
| SCHEMBL966037 | 0.86 | CNR2 (0.45) | CNR2CNR1HSD11B1MEN1KMT2A | |
| SCHEMBL963095 | 0.86 | CNR2 (0.45) | CNR2CNR1HSD11B1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2024349-B1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-20150231141-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC (US) | 2015-08-20 | — | — | US | disclosed |
| US-9006275-B2 | Compounds as cannabinoid receptor ligands and uses thereof | ABBVIE INC. (US) | 2015-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150231141-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, OPRL1 | CNR2 2/4885CNR1 1/4885HSD11B1 1629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.